Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3089-3094

  Small, Eric J ^a   Schellhammer, Paul F ^b   Higano, Celestia S ^b   Redfern, Charles H ^b   Nemunaitis, John J ^b   Valone, Frank H ^b   Verjee, Suleman S ^b   Jones, Lori A ^b   Hershberg, Robert M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROVENGE; SIPULEUCEL T; UNCLASSIFIED DRUG; PLACEBO; SIPULEUCEL-T; TISSUE EXTRACT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL STIMULATION; CLINICAL TRIAL; COLD SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; TREMOR; DRUG RESISTANCE; IMMUNOTHERAPY; MIDDLE AGED; MULTICENTER STUDY; PROSTATE TUMOR; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PLACEBOS; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 33746012881     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.5252     Document Type: Article

References (15)

1. Jemal A, Murray T, Ward E, et al: Cancer Statistics 2005. Ca J Cancer Clin 55:10-30, 2005
2. Vogelzang N: One hundred thirteen men with prostate cancer died today. J Clin Oncol 14:1753-1755, 1996
3. Tannock IF, deWit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
4. Petrylak D, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone in hormone refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
5. Small EJ, Fratesi P, Reese DM, et al: Immunotherapy of hormone refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18:3894-3903, 2000
6. Burch PA, Breen JK, Buckner JC. et al: Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6:2175-2182, 2000
7. Burch PA, Croghan GA, Gastineau DA, et al: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial. Prostate 60:197-204, 2004
8. Laus R, Yang DM, Ruegg CL, et al: Dendritic cell immunotherapy of prostate cancer: Preclinical models and early clinical experience. Cancer Res Ther Cont 11:1-10, 2001
9. Bubley GJ, Carducci M, Dawson N, et al: Eligibility and response guidlines for phase II clinical trials in androgen independent prostate cancer: Recommendations from the PSA Working Group. J Clin Oncol 17:3461-3467, 1999
10. Small EJ, Meyer M, Marshall ME, et al: Suramin therapy for patients with symptomatic hormone refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18:1440-1450, 2000
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
12. Wilcoxon F: Individual comparisons by ranking methods. Biomet Bull 1:80-83, 1945
13. Smaletz O, Scher HI, Small EJ, et al: A nomogram for overall survival of patients with progressive metastatic prostate cancer following castration. J Clin Oncol 20:3972-3982, 2002
14. Halabi S, Small EJ, Kantoff PW, et al: A prognostic model for predicting overall survival in men with hormone refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237, 2003
15. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Ca Inst 94:1458-1468, 2002